• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

Market Research and Analysis of N-3-(2-bromoacetyl)phenylmethanesulfonamide in the Chemical-Biomedical Field

The compound N-3-(2-bromoacetyl)phenylmethanesulfonamide, identified by the CAS registry number 2065-04-5, has garnered significant attention in the chemical-biomedical industry due to its unique properties and potential applications. This research brief aims to provide an in-depth analysis of the latest developments, market demands, and future prospects of this compound within the chemical-biomedical field.

The compound N-3-(2-bromoacetyl)phenylmethanesulfonamide is a derivative of methanesulfonamide, which is widely used in organic synthesis and drug development. Its structure incorporates a bromoacetyl group, which enhances its reactivity and bioavailability. Recent studies have highlighted its potential as a precursor for synthesizing bioactive molecules, particularly in the fields of oncology and neurodegenerative diseases.

Market demand for N-3-(2-bromoacetyl)phenylmethanesulfonamide has been driven by its role as an intermediate in drug discovery processes. The increasing focus on personalized medicine and the development of targeted therapies have further amplified its significance. According to industry reports, global suppliers are actively scaling up production to meet the rising demand from pharmaceutical companies and research institutions.

The purpose of this research is to evaluate the current market landscape of N-3-(2-bromoacetyl)phenylmethanesulfonamide, identify key drivers and challenges, and provide insights into future trends. This analysis is based on a comprehensive review of academic publications, industry reports, and supplier data.

To conduct this study, we employed a multi-faceted approach that included keyword searches in scientific databases (such as PubMed and ScienceDirect), analysis of market trends using tools like Statista and IBISWorld, and direct outreach to suppliers for real-time data. The results were synthesized to provide a holistic view of the compound's market dynamics.

The findings reveal that N-3-(2-bromoacetyl)phenylmethanesulfonamide is increasingly being utilized in preclinical studies for its ability to modulate key cellular pathways. Its role as an intermediate in the synthesis of kinase inhibitors has been particularly noteworthy. Additionally, its application in combinatorial chemistry has expanded its utility across diverse therapeutic areas.

In terms of supply chain dynamics, several global chemical manufacturers have established dedicated production lines for this compound. The Asia-Pacific region has emerged as a major production hub due to favorable regulatory environments and lower production costs. However, challenges such as raw material shortages and stringent regulatory requirements remain significant barriers to scaling up production.

In conclusion, N-3-(2-bromoacetyl)phenylmethanesulfonamide holds immense potential in the chemical-biomedical field, driven by its versatility in drug discovery applications. As the demand for bioactive intermediates continues to grow, it is anticipated that this compound will play an increasingly critical role in advancing therapeutic innovations.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)